PDCD1 and nasopharyngeal carcinoma: This may also explain why the response rate to anti-PD1 inhibitors such as monotherapy is relatively modest in recurrent/metastatic NPC [43,44] and also why there is a lack of consistent prognostic value of PD1/PD-L1 expression for NPC patients [45].